Log In
BCIQ
Print this Print this
 

ManNAc, N-acetyl-D-mannosamine

  Manage Alerts
Collapse Summary General Information
Company New Zealand Pharmaceuticals Ltd.
DescriptionIntermediate in sialic acid biosynthesis
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationMuscular atrophy
Indication DetailsTreat hereditary inclusion body myopathy (HIBM)
Regulatory Designation U.S. - Orphan Drug (Treat hereditary inclusion body myopathy (HIBM))
PartnerFortress Biotech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/17/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today